Shares of Novo Nordisk slid to €39.70, down 1.8%, extending a bruising week-long selloff that has erased roughly 12% since July 28. The Danish drugmaker reported Q2 results on August 4 that topped Wall Street estimates on both revenue and profit — then watched the stock plunge anyway. The disconnect tells a story investors need to understand.
The Headline Numbers Looked Good, but the Fine Print Spooked the Market
Novo posted adjusted earnings of $0.95 per share on $12.1 billion in revenue, beating forecasts of $0.78 and $10.94 billion respectively.
Management raised full-year guidance, now expecting adjusted sales and profit to range from flat to down 6%, a meaningful improvement from prior guidance of down 4% to 12%. Yet roughly DKK 2 billion of the quarter's sales came from rebate credits for prior periods, and sales costs were cut 13% during the company's biggest-ever product launch — strip both out and adjusted operating profit actually went backwards.
The Weight-Loss Pill Is Growing Fast but Missed the Target
The oral version of Wegovy generated DKK 3.22 billion in Q2 revenue, just below the DKK 3.27 billion analysts expected.
BMO attributed the decline to inventory destocking and lower-than-expected U.S. injectable Wegovy sales.
Still, cumulative prescriptions have passed five million, with the pace accelerating sharply — the most recent million took just four weeks versus eleven for the first. The pill's success, though, is dragging down average prices: Morningstar now sees gross margins settling in the mid-70s, down from the high 70s, given growing reliance on cheaper oral options.
The Pipeline Setbacks Are Piling Up
On July 31, Novo disclosed that its experimental cardiovascular drug Ziltivekimab missed its primary endpoint. Meanwhile, its next-generation obesity drug CagriSema failed to match Eli Lilly's tirzepatide on blood-sugar control, achieving only 1.9% HbA1c reduction versus 2.2%.
Goldman Sachs slashed CagriSema's peak sales estimate from $11.8 billion to $5 billion and trimmed profit forecasts by roughly 10% through 2030.
Analysts Are Cautious Despite Cheap Headline Valuation
Goldman Sachs, Barclays, UBS, and Jefferies all hold neutral ratings, while Bernstein rates the stock a sell.
The consensus 12-month target of $47.17 implies about 3% upside from pre-selloff levels — hardly a ringing endorsement. The obesity drug market may exceed $100 billion by 2030 , but with Eli Lilly pulling ahead on efficacy and pipeline breadth, investors are repricing how much of that prize Novo can capture.